Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques

Intervirology

Volumn 39, Issue 1-2, 1996, Pages 93-103

  Wagner, Ralf ^a   Deml, Ludwig ^a   Notka, Frank ^a   Wolf, Hans ^a   Schirmbeck, Reinhold ^b   Reimann, Jörg ^b   Teeuwsen, Vera ^c   Heeney, Jonathan ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Antigen delivery system; Human immunodeficiency virus 1; Immunogenicity; Virus like particles

Indexed keywords

CD8 ANTIGEN; ENVELOPE PROTEIN; EPITOPE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; MACACA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RODENT; SAFETY; T LYMPHOCYTE; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; ANTIBODY FORMATION; CD8-POSITIVE T-LYMPHOCYTES; CONSUMER PRODUCT SAFETY; EPITOPES; GENE EXPRESSION; GENE PRODUCTS, GAG; GENETIC VECTORS; HIV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNOGENETICS; MACACA MULATTA; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PROTEIN PRECURSORS; RECOMBINATION, GENETIC; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; RODENTIA;

EID: 0029796784     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150480     Document Type: Article

References (76)

1. Rcdfield RR, et al: A phase I evaluation of the safely and immunogenicity of vaccination with recombinant gp!60 in patients with early human immunodeficiency virus infection, Military Medical Consortium for Applied Retroviral Research, N Engl J Med 1991;324:1677-1684.
2. Gorse GJ, Frey SE, Patel G, Newman FK, Belshc RB: Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type I envelope glycoproteins, NIAID AIDS Vaccine Clinical Trials Network, Vaccine 1994;12:912-918.
3. Gorse GJ et al: HIV-1 recombinantgpl60vaccine given in accelerated dose schedules, NIAID AIDS Vaccine Clinical Trials Network, Clin Exp Immunol 1994;98:178-184.
4. Schwartz DH, et al: Induction of HIV-I neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-11IIB rgpl20 subunit vaccine, Lancet 1993:342:69-73.
5. Kovacs JA, et al: Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-ncgative volunteers by immunization with recombinant gpl60, J Clin Invest 1993:92:919-928.
6. Steimer KS, Haigwood NL: Importance of conformation on the neutralising antibody response to HIV-1 gpl20, Biotechnol Ther 1991: 2:63-89.
7. Carlson JR, et al: Vaccine protection of rhesus macaques against simian immunodeficiency virus infection, AIDS Res Hunt Retorviruses 1990:6:1239-1246.
8. Cranage MP, et al: Intrarcctal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus, Lancet 1992: 339:273-274.
9. Dcsrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, Daniel MD: Vaccine protection against simian immunodeficiency virus infection, Proc Natl Acad Sei USA 1989:86:6353-6357.
10. Johnson PR, et al: Inactivated whole SIV vaccine in macaques: Evaluation of protective efficacy against challenge with cell-free virus or infected cells, AIDS Res Hum Retroviruses 1992:8:1501-1505.
11. Johnson PR, et al: Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralising antibodies and confers protection against heterologous challenge, Proc Natl Acad Sci USA 1992:89:2175-2179.
12. Murphy Corb M, et al: Efficacy of SlV/del-taB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys, AIDS 1991;5:655-662.
13. Murphey Corb M, Ohkawa S, Davison Fair-bum B, Martin LN, Baskin GB, Langlois AJ, Mclntec M, Narayan O, Gardner MB: A for-malin-fixcd whole SIV vaccine induces protective responses that are cross-protective and durable, AIDS Res Hum Retroviruses 1992:8: 1475-1478.
14. Arthur LO, Bess JW Jr, Sowder RC, Bcnveniste RE, Mann DL, Chermann JC, Henderson LE: Cellular proteins bound to immunodeficiency viruses, Implications for pathogenesis and vaccines, Science 1992:258:1935-1938.
15. de Vries P, et al: Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines, Vaccine 1994:12:1443-1452.
16. Stott EJ: Anti-cell antibody in macaques, Nature 1991:353:393.
17. Daniel MD, Kirchot TF, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene, Science 1992,258:1938-1941.
18. Hu SL, Abrams K, Barber GN, Moran P, Zar-ling JM, Langlois AJ, Kuller L, Morton WR, Bcnveniste RE: Protection of macaques against SIV infection by subunit vaccines ofSIV envelope glycoprotein gpl60, Science 1992:255: 456-459.
19. Yasutomi Y, et al: A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge, J Virol 1995;69:2279-2284.
20. Hulskotte EGJ, Gcrctti AM, Siebeling KHJ, van Amerongen G, Cranage MP, Rud EW, Norlcy SG, de Vries P, Ostcrhaus ADME: Vac-cine-induced virus-neutralising antibodies and cytotoxic T cells do not protect macaques from experiment infection with simian immunodeficiency virus SIVmac32H (J5), J Virol 1995:69: 6289-6296.
21. Huang Y, Zhang I., Ho DD: Characterisation of ncf sequences in long-term survivors of human immunodeficiency virus type 1 infection, J Virol 1995:69:93-100.
22. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Viro-logic and immunologic characterisation of long-term survivors of human immunodeficiency virus type 1 infection, N Engl J Med 1995:332:201-208.
23. Rowland-Joncs S, et al: HIV-specific cytotoxic T-cells in HIV exposed but uninfected Gambian women, Nature Med 1995;1:59-64.
24. Bryson YJ, Pang S, Wei LS, Dickovcr R, Diagne A, Chen IS: Clearance of HIV infection in a pcrinatally infected infant, N Engl J Med 1995:332:833-838.
25. Paul WE: Can the immune response control HIV infection? Cell !995;82:177-182.
26. Robinson WE Jr, Montcfiori DC, Gillespie DH, Mitchell WM: Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterised by increased protein and RNA syntheses and infectious virus release, J Acquir Immune Defic Svndr 1989;2:33-42.
27. Robinson WE Jr, Montcfiori DC, Mitchell WM, Prince AM, Alter HJ, Dreesnian GR, Eichbcrg JW: Antibodv-dcpendcnt enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1 infected and passively immunized chimpanzees, Proc Natl Acad Sci USA 1989:86:4710-4714.
28. Robinson WE Jr, Kawamura T, Lake D, Masu-ho Y, Mitchell WM, Hersh EM: Antibodies to the primary immunodominant domain of human immunodeficiency virus type I (HIV-1) glycoprotein gp41 enhance HIV-l infection in vitro, J Virol 1990:64:5301 -5305.
29. Takeda A, Robinson JE, Ho DD, Dcbouck C, Haigwood NL, Ennis FA: Distinction of human immunodeficiency virus type I neutralisation and infection enhancement by human monoclonal antibodies to glycoprotein 120, J Clin Invest 1992:89:1952-1957.
30. Habeshaw JA, Dalglcish AG, Bountif TL, Newell AL, Wilks D, Walker LC, Manca F: AIDS pathogenesis: HIV envelope and its interaction with cell proteins, Immunol Today 1990:11: 418-425.
31. Young JA: HIV and HLA similarity, Nature 1988:333:215.
32. Golding H, et al: Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class 11 elicits immunosuppressive au-toantibodics capable of contributing to immune dysfunction in HIV I-infcclcd individuals, J Clin Invest 1989;83:1430-1435.
33. Blackburn R, Clerici M, Mann D, Lucev DR, Goedert J, Golding B, Shearer GM, Golding H: Common sequence in HIV I GP41 and HLA class II beta chains can generate crossreactive autoant bodies with immunosuppressive potential early in the course of HIV 1 infection, Adv Exp Med Biol 1991:303:63-69.
34. Weinhold KJ, Lyerly HK, Stanley SD, Austin AA, Matthews TJ, Bologncsi DP: HIV-l GP120-mediatcd immune suppression and lymphocyte destruction in the absence of viral infection, J Immunol 1989;142:3091-3097.
35. Amadori A, Chicco Bianchi L: B-ccll activation and HIV-l infection: Deeds and misdeeds, Immunol Today 1990:11:374-379.
36. Amadori A, et al: CD4 epitope masking by gp!20/anti-gpl20 antibody complexes, A potential mechanism for CD4+ cell function down-regulation in AIDS patients, J Immunol 1992:148:2709-2716.
37. Siliciano RF, Lawton T, Knall C, Karr RW, Berman P, Gregory T, Reinhcrz EL: Analysis of host-virus interactions in AIDS with anti-gpl20 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion, Cell 1988:54:561-575.
38. Tvlcr DS, Nastala CL, Stanley SD, Matthews TJ, Lyerly HK, Bologncsi DP, Weinhold KJ: GP120 specific cellular cytotoxicity in HIV-l seropositive individuals, Evidence for circulating CD 16+ effector cells armed in vivo with cytophilic antibody, J Immunol 1989:142: 1177-1182.
39. Cox WI, Tartaglia J, Paoletti E: Induction of cytotoxic T lymphocytes by recombinant cana-rvpox (ALVAC) and attenuated vaccinia (NY-VAC) viruses expressing the HIV-l envelope glycoprotein, Virology 1993:195:845-850.
40. Nair S, Zhou X, Huang I., Rouse BT: Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines, J Immunol Methods 1992:152: 237-243.
41. Reddy R, Nair S, Brvncstad K, Rouse BT: Liposomes as antigen delivery systems in viral immunity, Semin Immunol 1992;4:91-96.
42. Reddy R, Zhou F, Nair S, Huang L, Rouse BT: In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes, J Immunol 1992:148:1585-1589.
43. Heeg K, Kuon W, Wagner II: Vaccination of class I rnahjor histocompatibility complex (MHC)-rcstricted murine CD8+ cytotoxic T lymphocytes towards soluble antigens: Immu-nostimulating-ovalbumin complexes enter the class I MHC-rcstricled antigen pathway and allow sensitization against the immunodominant peptide, EurJ Immunol 1991:21:1523-1527.
44. Newman MJ, Wu JY, Gardner GB, Munroc KJ, Leombruno D, Recchia J, Kensil CR, Coughlin RT: Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T Ivmpho-cvtc responses, J Immunol 1992:148:2357- 2362.
45. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells, Lancet 1995:345:1342-1344.
46. Michel ML, Mancini M, Riviere Y, Dormont D, Tiollais P: T- and B-lvmphocyte responses to human immunodeficiency virus (HIV) type I in macaques immunized with hybrid HIV/hcpatitis B surface antigen particles, J Virol 1990;64:2452-2455.
47. Ada G, Koff W, Petricciani J: The next steps in HIV vaccine development, AIDS Res Hum Retroviruses 1992:8:1317-1319.
48. W'agncr R, Dcml L, Flicssbach H, W'anner G, Wolf H: Assembly and extracellular release of chimeric HIV-l PrSSgag retrovirus-like particles, Virology 1994:200:162-175.
49. Wagner R, Demi L, Fitzon T, Wolf H: HIV Assembly: Target for antiviral therapy and basis of a rationally designed candidate vaccine: in Chanock RM, Brown F, Ginsberg HS, Norr-by E (eds): Vaccines 95: Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor, Cold Spring Harbor Laboratory Press, 1995, pp 347-356.
50. r55™ protein: Understanding of the mechanism of virus assembly as a basis for the development of novel therapeutics and vaccines: in Odile R (ed): Retroviruses of Human AIDS and Related Animal Diseases, Mamcs-La-Co-quettc, Colloque dcs Cent Gardes, 1994, pp 299-307.
51. Ghcysen D, Jacobs E, dc Forcsta F, Thiriart C, Francotte M, Thines D, De Wilde M: Assembly and release of HIV-l precursor Pr55,?a, e viruslike particles from recombinant baculovirus-infccted insect cells, Cell 1989:59:103-112.
52. Wagner R, Fliessbach H, Wanner G, Motz M, Niedrig M, Deby G, von Brunn A, W'olf H: Studies on processing, panicle formation, and immunogenicity of the HIV-l gag gene product: A possible component of a HIV vaccine, Arch Virol 1992;127:117-137.
53. von Poblotzki A, W'agncr R, Niedrig M, W'anner G, Wolf H, Modrow S: Identification of a region in the P r 5 5gag- pol y pro te i n essential for HIV-l panicle formation, Virology 1993:193: 981-985.
54. 5.?iig/V3 chimeric vaccinia viruses, J Gen Virol 1993:74:1261-1269.
55. Wagner R, Dcml L, Schirmbeck R, Reimann J, Wolf II: Induction of MHC class 1-restricted C'D8 positive cytolytic T-ccll response by chimeric HIV-l virus-like particles in vivo: Implications on HIV-vaccine development: in Seiler FR, Schulz G (eds): Behring Institute Research Communications: Modem Vaccine Design, Marburg, Behring Institute Research Communications, 1994, pp 23-34.
56. Wagner R, Demi L, Wolf H: Polyvalent, recombinant HIV-l virus-like panicles: Novel HIV-l vaccine strategies, Antibiot Chemother 1994:46:48-61.
57. Steimer KS, Haigwood NL: Immunization of primates with native, recombinant HIV-SF2 gpl20 generates broadly effective neutralising antibodies directed to confonnational epitopes, AIDS Res Hum Retroviruses 1992;8: 1391.
58. Rucgg CL, Strand M: A synthetic peptide with sequence identity to the transmembrane protein GP4I of HIV-l inhibits distinct lymphocyte activation pathways dependent on protein kinase C and intracellular calcium influx, Cell Immunol 1991;137:1-13.
59. Ruegg CL, Monell CR, Strand M: Inhibition of lymphoproliferation by a synthetic peptide w ith sequence identity to gp4l of human immunodeficiency virus type 1, J Virol 1989;63: 3257-3260.
60. Yamada M, Zurbriggen A, Oldstone MB, Fuji-nami RS: Common immunologic determinant between human immunodeficiency virus type 1 gp41 and astrocytes, J Virol 1991:65: 1370-1376.
61. Germain RN: Antigen presentation, The second class story, Nature 1991:353:605-607.
62. Germain RN, Hendrix I.R: MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding, Nature 1991:353:134-139.
63. Yewdcll JW, Bennink JR: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes, Adv Immunol 1992; 52:1-123.
64. Townsend A, Bodmer H: Antigen recognition by class I-restricted T lymphocytes, Annu Rev Immunol 1989;7:601-624.
65. Papsidero LD, Sheu M, Ruscetti PA'; Human immunodeficiency virus type I-neutralising monoclonal antibodies which react with pi7 core protein: Characterisation and epitope mapping., I Virol 1989;63:267-272.
66. Nixon DF, Townsend AR, Elvin JG, Rizza CR, Gallwey J, McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides, Nature 1988;336:484-487.
67. Phillips RE, et al: Human immunodeficiency virus genetic variation that can escape cyto-toxicTcell recognition, Nature 1991:354:453-459.
68. Schirmbcck R, Demi L, Melber K, Wolf H, Wagner R, Reimann J: Priming of class 1-rcstrictcd cytotoxic T lymphocytes by vaccination with recombinant protein antigens, Vaccine 1995;13:857-865.
69. Wagner R, Demi L, Schirmbeck M, Niedrig M, Reimann J, Wolf H: Construction, expression and immunogenicity of chimeric HIV-1 viruslike particles, Virology 1996,220: in press.
70. Griffiths JC, Harris SJ, Layton GJ, Bcrrie EL, French TJ, Bums NR, Adams SE, Kingsman AJ: Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: Induction of cytotoxic T-ccll and humoral responses by a Gag: V3 fusion, J Virol 1993:67: 3191-3198.
71. Layton GT, Harris SJ, Gearing AJ, Hill Perkins M, Cole JS, Griffiths JC, Bums NR, Kingsman AJ, Adams SE: Induction of HIV-specific cytotoxic T lymphocytes in vivo with hybrid HIV-1 V3:Ty-virus-likc particles, J Immunol 1993: 151:1097-1107.
72. Schirmbeck R, Melber K, Mcrtens T, Reimann J: Antibody and cytotoxic T-ccll responses to soluble hepatitis B vims (HBV) S antigen in mice: Implication forthc pathogenesisof HBV-induecd hepatitis, J Virol 1994:68:1418- 1425.
73. Mooie JP: Back to primary' school, Nature 1995:376:115.
74. Slobod KS, Hurwitz JL: Does envelope V3 peptide comprise the principal neutralising determinant for HIV? Vaccine 1995:13:129.
75. Koup RA, Ho DD: Shutting down HIV, Nature 1994:370:416.
76. Koup RA, Safril JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome, J Virol 1994:68:4650-4655.